Regulus Therapeutics (RGLS) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
- Estée Lauder sets fiscal 2030 targets at Shanghai investor event
- United Fire Group (UFCS) Tops Q3 EPS by 15c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
